All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

GLP-1 adoption in Connecticut

Connecticut has an estimated 150,999 GLP-1 users across 9 counties. Average estimated adoption is 1.5 percentage points below the national rate of 5.7%.

Last reviewed |Reviewed by the FormBlends Editorial Standards Team

4.2%

Est. adoption rate

150,999

Est. users

30.7%

Avg adult obesity

3,611,317

Adult population

State facts for search and AI answers

What makes the Connecticut GLP-1 page useful

This page ties the statewide answer to county-level demand, coverage context, and practical access checks. The goal is to help readers move from a broad state estimate to the local county or provider question that actually matters.

State signal

Connecticut: 9 counties, 150,999 estimated GLP-1 users

State pages summarize the county-level demand model before readers drill into local pages.

Model inputs

Average adoption 4.2%; average adult obesity 30.7%

The model uses CDC PLACES obesity prevalence, Census population, and KFF national GLP-1 utilization.

Coverage context

Connecticut Medicaid covers some non-GLP-1 weight-loss medications, but excludes GLP-1s for obesity. According to KFF (2026-01-16), federal Medicaid rules require GLP-1 coverage for type 2 diabetes, cardiovascular disease, and sleep apnea indications. Obesity coverage is optional and varies by state.

Coverage policy can make real access higher or lower than projected local demand.

How to use this page

Find counties with the strongest demand signal, then verify coverage, provider access, and pharmacy source before starting care.

This is a local planning page, not a prescription recommendation.

Counties ranked by estimated adoption

Adoption strip: each bar is one county, tallest = highest estimated rate
County adoption strip. Tallest bar = highest projected adoption in Connecticut.
Ranked counties in Connecticut by estimated GLP-1 adoption.
RankCountyPopulationObesity %Est. adoptionEst. users
1South Central Connecticut Planning Region571,29833.9%4.6%26,337
2Southeastern Connecticut Planning Region280,29333.1%4.5%12,641
3Capitol Planning Region977,16532.4%4.4%43,093
4Northeastern Connecticut Planning Region95,68732.4%4.4%4,220
5Naugatuck Valley Planning Region451,88730.7%4.2%18,889
6Lower Connecticut River Valley Planning Region175,24429.8%4.1%7,115
7Northwest Hills Planning Region112,69629.2%4.0%4,474
8Greater Bridgeport Planning Region326,38128.4%3.9%12,631
9Western Connecticut Planning Region620,66625.6%3.5%21,599

How Connecticut fits the national picture

The KFF 2024 poll pegged national adult GLP-1 use at 5.7%. Applied to Connecticut's obesity profile, the model projects 4.2% of adults are on a GLP-1 medication. That matches the county-level obesity data from CDC PLACES (2023) more than any measured prescription count; the state's real share could be higher in urban areas with broad commercial coverage, or lower in rural regions where prescriber access is limited.

Compounded semaglutide and tirzepatide complicate the picture. After the FDA shortage resolution in late 2024 and early 2025, compounded supply dropped sharply. Brand-name utilization rose. The county numbers here don't separate brand vs. compounded, because no public dataset does yet.

Decision path

How should I use the Connecticut GLP-1 map?

This state view is a demand and access signal, not a prescription recommendation. Use it to understand where GLP-1 need may be concentrated, then pressure-test provider availability, insurance rules, and pharmacy quality before starting care.

State
Connecticut
Counties
9
Est. users
150,999
Avg adoption
4.2%

Step 1

Find county context

County estimates help separate broad statewide demand from the local access picture a patient actually experiences.

Review counties

Step 2

Check coverage and price

Connecticut access depends on payer policy, prior authorization, cash-pay pricing, and whether local clinicians can support follow-up.

Check coverage path

Step 3

Decide on care route

If local access is thin or pricing is unclear, a supervised telehealth assessment can clarify eligibility and next steps.

Compare provider options
Start provider review in ConnecticutReview pharmacy oversight

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

CDC PLACES

Dataset

Used for county-level obesity inputs in local GLP-1 adoption estimates.

KFF GLP-1 utilization polling

Dataset

Used as the national anchor for estimated GLP-1 adoption.

STEP 1 semaglutide obesity trial

Trial

Primary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.

Frequently asked questions

How is GLP-1 adoption calculated for Connecticut counties?
We multiply each county's CDC PLACES 2023 adult obesity prevalence by a scaling factor k = 0.1361, which comes from the KFF 2024 figure of 5.7% national GLP-1 adoption divided by the 41.9% national adult obesity rate. That gives an estimated per-county adoption %. Multiply by Census ACS 5-year 2022 county population to get projected users. Connecticut shows 4.2% state-average adoption under this model.
Why is Connecticut's number 1.5 percentage points below the national average?
Adult obesity prevalence in Connecticut averages 30.7% (CDC BRFSS 2024, state-level). The national average is 41.9%. The model links adoption linearly to obesity, so states above the national obesity rate come out above the national adoption estimate, and vice versa. Real variation also depends on commercial insurance coverage and Medicaid GLP-1 policy, both of which differ significantly by state.
Do Medicaid enrollees in Connecticut get GLP-1 coverage?
Connecticut Medicaid covers some non-GLP-1 weight-loss medications, but excludes GLP-1s for obesity. According to KFF (2026-01-16), federal Medicaid rules require GLP-1 coverage for type 2 diabetes, cardiovascular disease, and sleep apnea indications. Obesity coverage is optional and varies by state.
What studies back up GLP-1 weight loss expectations?
The STEP 1 trial (Wilding et al., NEJM, 2021) enrolled 1,961 adults on 2.4mg weekly semaglutide over 68 weeks and saw mean body weight change of negative 14.9% vs negative 2.4% on placebo. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) tested tirzepatide in 2,539 adults over 72 weeks and saw negative 20.9% at 15mg weekly. Both were randomized, double-blind, and placebo-controlled.
How often does the Connecticut county data refresh?
CDC PLACES releases annually in late summer. Census ACS 5-year estimates release every December. KFF reruns its GLP-1 utilization poll roughly twice a year. We re-run the full county model whenever any of those update, and the last-reviewed date at the top of every page reflects the most recent refresh.

Sources

Related reading

glp1

Compounded Semaglutide Guide

How compounded semaglutide access works, what to ask a pharmacy, and how to compare safety and pricing.

glp1

Semaglutide Cost Comparison

Compare semaglutide pricing across brand, insurance, cash-pay, and compounded access paths.

experience

Tirzepatide Side Effects Complete Guide

Common tirzepatide side effects, warning signs, and practical management steps to discuss with a clinician.

glp1

Semaglutide Injection Sites

How to rotate semaglutide injection sites and reduce irritation, bruising, and technique problems.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

2026 GLP-1 Telehealth Report

105 providers scored on price, safety, compliance, and patient experience.

Compounded GLP-1 ZIP Lookup

State pharmacy-board posture and telehealth access for US ZIP codes.

America on GLP-1 Map

County-level adoption estimates using CDC, Census, and KFF inputs.

Looking for GLP-1 care in Connecticut?

FormBlends ships compounded semaglutide and tirzepatide to Connecticut with licensed telehealth consultations.

Start your assessment

Estimated adoption figures are modeled projections from public data, not measured prescription counts. This page is general information, not medical advice. Individual results vary. Talk to a licensed healthcare provider before starting any medication.